XML 33 R26.htm IDEA: XBRL DOCUMENT v3.26.1
Summary of Significant Accounting Policies - Summary of Segment Profit or Loss Including Significant Segment Expenses (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Segment Reporting Information, Profit (Loss) [Abstract]    
Collaboration revenue $ 1,046 $ 3,674
Less:    
Compensation and benefits 8,248 16,557
Lab expenses and outside research services 3,447 3,224
Clinical supply costs 1,379 3,074
Clinical trials 3,384 7,013
Support functions 6,300 8,286
Other segment expenses [1] 3,207 10,215
Total operating expenses 25,965 48,369
Loss from operations (24,919) (44,695)
Other income, net 1,989 4,224
Loss before income taxes $ (22,930) $ (40,471)
[1] Other segment expenses include consultants & contractor expense, contra-R&D expense for GSK collaboration, depreciation expense, impairment loss, restructuring expense, and stock-based compensation expense.